DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,218,613 | -31.7% | 4,835 | -28.1% | 2.00% | -28.2% |
| Q4 2022 | $1,785,215 | -8.3% | 6,726 | -9.4% | 2.78% | -0.7% |
| Q3 2022 | $1,947,000 | +4.0% | 7,427 | +0.6% | 2.80% | +9.2% |
| Q2 2022 | $1,872,000 | -19.7% | 7,384 | -7.0% | 2.56% | -1.5% |
| Q1 2022 | $2,330,000 | -13.4% | 7,944 | -2.9% | 2.60% | -8.8% |
| Q4 2021 | $2,692,000 | +12.7% | 8,183 | +4.3% | 2.85% | +11.4% |
| Q3 2021 | $2,388,000 | -10.3% | 7,844 | -21.0% | 2.56% | -6.0% |
| Q2 2021 | $2,663,000 | +16.3% | 9,923 | -2.5% | 2.72% | +9.4% |
| Q1 2021 | $2,290,000 | +1.3% | 10,173 | 0.0% | 2.49% | -0.1% |
| Q4 2020 | $2,260,000 | -2.2% | 10,173 | -5.2% | 2.49% | -15.6% |
| Q3 2020 | $2,310,000 | +20.7% | 10,728 | -0.9% | 2.96% | +11.7% |
| Q2 2020 | $1,914,000 | +8.0% | 10,823 | -1.9% | 2.65% | +3.0% |
| Q1 2020 | $1,773,000 | +121.9% | 11,038 | +133.7% | 2.57% | +163.9% |
| Q4 2019 | $799,000 | – | 4,724 | – | 0.97% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |